Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The current state of the art in ALL and how novel agents are impacting the field

Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the current state of the art in acute lymphoblastic leukemia (ALL), commenting on how the use of tyrosine kinase inhibitors (TKIs) and antibody therapies in the frontline setting have transformed the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.